TargetMol
 |
||
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global small molecule suppliers with over 5000 inhibitors and 80+ compound libraries in stock. TargetMol offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, activator, APIs and natural compounds for laboratory and scientific use. Website : www.targetmol.com | ||
SARS-CoV-2 - Tocilizumab - Therapeutic Candidates
Tocilizumab is a humanized monoclonal antibody that blocks the action of interleukin-6 (IL-6) receptors. The IL-6 receptor has two forms: the membrane form mIL6R and the soluble form sIL-6R. Tocilizumab can bind specifically to sIL-6R and mIL-6R and inhibit the transduction signal. It is commonly used in rheumatoid arthritis as it is immunosuppressive.
Since the beginning of the COVID-19 pandemic, it has been shown that in patients severely affected by COVID-19 caused by the SARS-CoV-2 virus, there was a "cytokine storm" that would be a major cause of mortality as the inflammatory overreaction would destroy tissues.
IL-6 is thought to be one of the mediators of the inflammation that follows the immune response against SARS-CoV-2 in the pulmonary alveoli and thus one of the cytokines responsible for this "cytokine storm" phenomenon. Tocilizumab may therefore be a good candidate for treatment of COVID-19.
Resultado da sua pesquisa : 5 produto encontrado
Refine sua procura :
RUOCE / IVD
- Biochemicals 5
Referência
Descrição
Cond.
Price Bef. VAT
‹
›